E-Cadherin and Ki-67 Expression Profiles in Non-Small Cell Lung Cancer: Immunohistochemical Analysis and Correlation with Clinicopathological Features and Survival Outcomes
International Journal of Drug Delivery Technology · 29.06.2026 · 16 (59s)
DOI: 10.25258/ijddt.16.59s.30 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 29.06.2026. Verfasst von Sri Melati Munir und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Lung cancer remains the leading cause of cancer death worldwide. Epithelial-to-mesenchymal (EMT) transition markers, such as E-Cadherin, and proliferation indices, such as Ki-67, become markers that can be assessed by immunohistochemistry (IHC) and can act as significant prognostic biomarkers. The simultaneous expression profile of ECadherin and Ki-67 in KPKBSK lung cancer patients in Indonesia is still rare. This study aimed to analyze the relationship between the immunohistochemical expression of E-Cadherin, EGFR, and Ki-67 in KPKBSK tissue specimens and to correlate the results of EGFR, E-Cadherin, and Ki-67 expression examination with pathological clinical parameters and overall survival. Materials and Methods: This cross-sectional study involved 40 histopathologically confirmed KPKBSK patients, evaluated through immunohistochemical staining for E-Cadherin, EGFR, and Ki-67 performed on formalin-fixed paraffinembedded (FFPE) tissue blocks and interpreted using the Immunoreactive Score (IRS) method, which was classified as low or high expression. Pathological clinical data, including age, sex, smoking history, tumour stage, and overall survival, were recorded. Statistical analysis includes descriptive statistics, the Mann-Whitney test, and the exact Fisher test.
Results
The total number of patients who were the subjects of the study was 40 patients (mean age 57.9 ± 11.8 years; range 22-79 years), with a predominance of males of 65%. The majority of patients (62.5%) showed disease at Stage IVA. Specifically, low expression of E-Cadherin was detected in 90% of patients (n = 36), while low expression of EGFR was universal (100%). High expression of Ki-67 was observed at 62.5% (n=25). The dominant phenotypic biomarkers were low E-Cadherin and high Ki-67 (55%), indicating a proliferative-mesenchymal phenotype. Overall, patient survival averaged 3.0 months among all patients. Low expression of E-Cadherin was associated with a longer median survival numerically (3.0 months) compared to high expression (3.0 months), although it was not statistically significant (p = 0.82). Ki-67 expression did not significantly affect survival outcomes (p=0.85). This finding likely reflects the advanced stage of disease within the cohort rather than the effects of intrinsic biomarkers.
Conclusions
This study demonstrated significant downregulation of E-Cadherin and the absence of EGFR overexpression, indicating a mesenchymal tumor phenotype with poor prognostic implications. Low E-Cadherin and high Ki-67 yields have the potential to obtain anti-proliferative therapy. The results of this study show that prospective studies are still needed that integrate IHC biomarkers with molecular profiles in lung cancer patients in Indonesia
Zitieren
APA
Munir, S. M., Harahap, W. A., Basyar, M., & Hilbertina, N. (2026). E-Cadherin and Ki-67 Expression Profiles in Non-Small Cell Lung Cancer: Immunohistochemical Analysis and Correlation with Clinicopathological Features and Survival Outcomes. International Journal of Drug Delivery Technology, 16(59s). https://doi.org/10.25258/ijddt.16.59s.30
Vancouver
Munir SM, Harahap WA, Basyar M, Hilbertina N. E-Cadherin and Ki-67 Expression Profiles in Non-Small Cell Lung Cancer: Immunohistochemical Analysis and Correlation with Clinicopathological Features and Survival Outcomes. International Journal of Drug Delivery Technology. 2026;16(59s). doi:10.25258/ijddt.16.59s.30
BibTeX
@article{Munir2026,
author = {Munir, Sri Melati and Harahap, Wirsma Arief and Basyar, Masrul and Hilbertina, Noza},
title = {E-Cadherin and Ki-67 Expression Profiles in Non-Small Cell Lung Cancer: Immunohistochemical Analysis and Correlation with Clinicopathological Features and Survival Outcomes},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {59s},
doi = {10.25258/ijddt.16.59s.30}
}
EUVIMED